Drug titration patterns and HbA 1c levels in type 2 diabetes

Area of Science:

• Endocrinology
• Pharmacology
• Health Services Research

Background:

• Type 2 diabetes mellitus (T2DM) management requires effective oral antidiabetes drug (OAD) therapy and regular monitoring.
• Glycaemic control, assessed by haemoglobin A1c (HbA1c), is critical for preventing long-term diabetes complications.

Purpose of the Study:

• To evaluate the utilization of OADs, the frequency of HbA1c testing, and the status of glycaemic control in patients with T2DM.
• To identify factors influencing HbA1c testing and OAD regimen titration.

Main Methods:

• Retrospective analysis of claims data from the Integrated Healthcare Information Services (IHCIS) National Managed Care Benchmark Database (2000-2006).
• Inclusion criteria: at least two claims for T2DM diagnosis and one 90-day OAD treatment period.
• Multivariable logistic regression was used to analyze predictors of HbA1c testing and OAD regimen up-titration.

Main Results:

• Metformin (MET) was the most common initial OAD (41.3%), followed by sulfonylurea (SFU) (34.3%).
• Only 51.5% of patients underwent HbA1c testing within 90 days of OAD initiation. A significant proportion of patients on MET (65%) and SFU (58%) did not have their initial regimen titrated.
• Despite a reduction in inadequate glycaemic control from 68.5% to 46.9% within 90 days, predictors of low HbA1c testing included SFU use and older age. Factors associated with reduced OAD up-titration included specific OADs (TZD, SFU+MET, TZD+MET) and younger age.

Conclusions:

• Current OAD management in T2DM patients often involves inadequate stepwise treatment intensification and insufficient regimen titration.
• Low rates of HbA1c testing and suboptimal glycaemic control highlight significant gaps in diabetes care.
• There is a need for improved strategies to ensure timely OAD adjustments and consistent HbA1c monitoring to optimize glycaemic control in T2DM patients.